Strategic Focus Target late-stage COPD treatment opportunities by aligning with Free Flow Medical’s next-generation coil technology and its established network of top clinical experts in the US and Europe to expand clinical adoption and patient access.

Clinical Expertise Leverage the track record of Mark Mathis and the team behind PneumRx to position advanced coil solutions for both heterogeneous and homogeneous disease, highlighting proven potential through prior acquisition success and ongoing R&D.

Regulatory Edge Capitalize on the company’s ISO certification and CE Mark for FreeFlow Coil to pursue regulatory-driven market entry strategies, reimbursement discussions, and cross-border pilot programs with hospital systems and payers.

Funding Readiness With current revenue in the low millions and approximately $4.9M in funding, target partnerships with medical device investors and larger distributors to accelerate scale, manufacturing capacity, and broader sales reach.

Partnership Potential Engage key distributors and large healthcare suppliers aligned with major industry players to expand channel coverage, leveraging Free Flow Medical’s niche in COPD device technology to differentiate offerings in a competitive landscape.